U.K. House Of Lords Declares Amgen's Erythropoietin Patent Invalid
In yet another twist in one of the most dramatic weeks of the seven-year patent battle between biotech rivals Amgen Inc. and Transkaryotic Therapeutics Inc., the U.K.'s House of Lords has...To view the full article, register now.
Already a subscriber? Click here to view full article